Catalent, Inc. (CTLT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Somerset, NJ, United States. Der aktuelle CEO ist Alessandro Maselli.
CTLT hat IPO-Datum 2014-07-31, 17,000 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $11.52B.
Catalent, Inc. is a leading contract development and manufacturing organization that provides comprehensive solutions for drugs, biologics, cell and gene therapies, and consumer health products to pharmaceutical, biotechnology, and healthcare companies worldwide. Operating through four segments—Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services—the company offers specialized capabilities including softgel capsule manufacturing, biologic cell-line development, parenteral dose form production, oral delivery formulations, and clinical trial supply chain management. Its services span from early-stage formulation and development through commercial manufacturing and distribution, serving diverse markets including prescription and over-the-counter medications, dietary supplements, animal health products, and medical devices. Headquartered in Somerset, New Jersey, Catalent has established itself as a critical partner for companies seeking to bring innovative therapeutics and healthcare products to market efficiently and at scale.
